Nintedanib-d3

• Description:

  Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

• Product Name Alternative:

  BIBF 1120-d3

• UNSPSC:

  12352005

• Target:

  FGFR; PDGFR; VEGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C([2H])([2H])[2H])CC4)=O)C=C3)/C5=CC=CC=C5)OC

• Molecular Formula:

  C31H30D3N5O4

• Molecular Weight:

  542.64

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) . J Med Chem, 2009, 52 (14), 4466-4480.|[3]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68 (12), 4774-4782.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1624587-84-3]